V8 Peptides — Engineered Performance
Research Library
BPC-157 and TB-500: US Regulatory Documents in 2026
BPC-157Regulatory

BPC-157 and TB-500: US Regulatory Documents in 2026

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

As read on 17 November 2026: neither BPC-157 nor TB-500 is named in 21 CFR 216.23(a); FDA's July 2026 briefing documents state that no USP or NF monograph applies to either and that the criteria "weigh against" listing; HHS's draft, non-binding policy of 30 October 2026 names both in Appendix A; and WADA's 2026 List names BPC-157 under S0 and TB-500 under S2.3. This summarizes documents only and gives no legal conclusion or advice.

People often ask about BPC-157 and TB-500 together, and several agencies have published documents that name both. This article sets those documents side by side as read on 17 November 2026: FDA's section 503A pages and its July 2026 advisory committee materials, a Federal Register notice and policy document from the Department of Health and Human Services (HHS), and the World Anti-Doping Agency (WADA) 2026 Prohibited List. It uses primary documents only, states what each says, and draws no legal conclusion; it does not say whether any activity is lawful, and it is not advice. The library overview is research peptide legal status in the US.

V8 products are labeled for laboratory research use only. This article describes documents and states no legal conclusion.

What each compound is, as the documents describe it

FDA's briefing document describes TB-500 as "a peptide containing seven amino acids with an acetyl group at the N-terminal Leucine (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH)." Appendix B of the HHS policy document gives TB-500 acetate the molecular formula C38H68N10O14·CH3COOH and a molecular weight of 949.1 g/mol, and gives BPC-157 acetate the formula C62H98N16O22·xCH3COOH with a molecular weight of 1419.54 + x(60.05) g/mol and the sequence H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH. A 2012 doping-control paper (Ho et al.) describes "a veterinary preparation known as TB-500" containing a synthetic version of the peptide LKKTETQ, the 17-23 segment of the protein thymosin β4, with artificial acetylation of the N-terminus. Cox and colleagues (2017) describe BPC 157, sequence GEPPPGKPADDAGLV, as identified in confiscated vials. The regulatory documents below refer to "TB-500-related" and "BPC-157-related" substances in free base and acetate forms, not to full-length thymosin β4. Background on the compounds is in the BPC-157 and TB-500 overviews and the TB-500 vs thymosin beta-4 comparison.

FDA's section 503A framework

FDA's page on bulk drug substances under section 503A (read 17 November 2026) states that state-licensed physicians and pharmacists compounding under section 503A "may only compound drug products using bulk drug substances" that comply with an applicable USP or NF monograph, are components of FDA-approved drug products, or appear on FDA's 503A bulks list. The regulation holding the list, 21 CFR 216.23(a) (eCFR, read 17 November 2026), names six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. Neither BPC-157 nor TB-500 is among them.

FDA's briefing documents for July 2026

For the 23 July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, FDA published separate evaluations of each substance. Both state that there is no applicable USP or NF drug substance monograph for the substance or its acetate form and that neither is a component of an FDA-approved drug. Both conclude that FDA staff believe the evaluation criteria "weigh against" placing the substance on the 503A bulks list.

ItemBPC-157 evaluationTB-500 evaluation
FDA documentfda.gov/media/193343/downloadfda.gov/media/193349/download
Evaluation date11 May 202615 May 2026
Use stated in the evaluationNot summarized in this articleEvaluated for "wound healing"
NominatorsTwo nominations, both withdrawn by the nominatorsOne nomination, withdrawn by the nominator
FDA's statement on listingCriteria "weigh against" placing either form on the listCriteria "weigh against" placing either form on the list
Characterization finding"not well-characterized"; inconsistent naming; data on impurities, aggregates, microbial quality and endotoxins lacking"not physically and chemically well characterized"; inconsistent naming; impurity, aggregate, microbial and endotoxin tests not found in public literature or the certificate provided

The agenda document (fda.gov/media/193342/download) states for both substances that the nominations were withdrawn by the nominators and that "FDA is electing to proceed with the presentation" to the committee. FDA's event page says advisory committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." The TB-500 evaluation also says FDA is concerned about the potential for immunogenicity of TB-500 in forms given by the subcutaneous or intramuscular routes because of potential aggregation and peptide-related impurities. This article did not find an FDA vote record; the only description of the committee's vote that was found is in the HHS document below.

FDA's Category 2 page

FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (read 17 November 2026) lists both substances under "Bulk drug substances nominated but withdrawn," described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators." For BPC-157 it says compounded drugs "may pose risk for immunogenicity for certain routes of administration" and that "FDA has identified no, or only limited, safety-related information for the proposed routes of administration." For "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," it says compounded drugs "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities" and that FDA "lacks important information regarding any safety issues raised by this drug."

The HHS notice and policy document

The Federal Register notice of 30 October 2026 (91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496) announces a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It states that HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A," that the policy "does not establish any rights for any person and is not binding on HHS or the public," and that HHS may revisit it "if, among other things, a safety signal or product quality issue arises." Appendix A of the policy document lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.

Appendix B says of TB-500: "TB-500 was in Category 2 from September 29, 2023, until April 22, 2026, and neither the placement nor the removal changed its status under section 503A; CDER recommended against listing either form, and the PCAC voted in favor of both forms." Its justification cites changed characterization records (lot-specific certificates from FDA-registered manufacturers), documented historical use, and a view that safety concerns are "inferential rather than observed." It says enforcement discretion for TB-500 acetate is appropriate for "subcutaneous or intramuscular" forms compounded from API accompanied by a conforming certificate of analysis. For BPC-157 it states the Category 2 period ran "from September 2023 until April 22, 2026," that the PCAC "voted in favor of inclusion," and that discretion is appropriate for subcutaneous, intramuscular, oral and topical forms.

The policy document also states the Secretary's determination that the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk" (the sentence continues beyond this quotation). It is quoted as worded and not interpreted here. The Federal Register notice itself does not mention research-use-only materials.

The WADA 2026 Prohibited List

The List states it "shall come into effect on 1 January 2026." Section S0, "Non-approved substances," is prohibited at all times (in- and out-of-competition), all its substances are Specified Substances, and it names BPC-157 among examples of the class. Section S2, "Peptide hormones, growth factors, related substances, and mimetics," is also prohibited at all times, with all substances non-Specified, and S2.3 lists "Thymosin-ß4 and its derivatives e.g. TB-500" among growth factors and growth factor modulators. Detection work is published for both: Cox and colleagues (2017) report a urine method for BPC 157 with a limit of detection of 0.1 ng/mL, and Ho and colleagues (2012) report detection of N-acetylated LKKTETQ at 0.01 ng/mL in equine urine.

Side by side

DocumentBPC-157TB-500
21 CFR 216.23(a)Not listedNot listed
FDA briefing documentNo USP/NF monograph; not an approved-drug component; criteria "weigh against" listingSame statements
FDA Category 2 pageUnder nominated but withdrawnUnder nominated but withdrawn, as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"
HHS policy, Appendix AListedListed
HHS policy, Appendix BCategory 2 from September 2023 to 22 April 2026Category 2 from 29 September 2023 to 22 April 2026
WADA 2026 ListS0, named as an exampleS2.3, "Thymosin-ß4 and its derivatives e.g. TB-500"

Dates in this article

DateEventSource
September 2023Category 2 period begins (BPC-157 "September 2023"; TB-500 29 September 2023)HHS policy document
1 January 2026WADA 2026 Prohibited List takes effectWADA
16 April 2026Federal Register notice of the July PCAC meeting (91 FR 20465)Federal Register
22 April 2026End of the Category 2 period for bothHHS policy document
11 and 15 May 2026FDA evaluations dated (BPC-157; TB-500)FDA briefing documents
23 July 2026PCAC meeting day for both substancesFDA agenda document
30 October 2026HHS notice published, 91 FR 68526Federal Register
17 November 2026Date these documents were read—

Limits of this article

This article reads FDA's evaluations for their introductions, nomination notes and conclusions, not every page. It does not cover state law, scheduling, customs and import rules or foreign regulation, and it does not assess whether any seller or activity complies with any law. Documents can change after 17 November 2026, so the originals listed in the references should be read directly. Related reading: BPC-157 vs TB-500, vetting a research peptide supplier, what are research peptides and how research peptides are shipped. Product pages for BPC-157 and TB-500 list specifications, and the COA page lists certificates where published.

Frequently asked questions

Are BPC-157 or TB-500 named in the regulation listing 503A bulk substances?

No. 21 CFR 216.23(a), as read on 17 November 2026, names six other substances.

What did FDA's briefing documents conclude for each?

For both BPC-157 and TB-500, FDA staff stated that the evaluation criteria weigh against placing the substance on the 503A bulks list, and that no USP or NF monograph applies and neither is a component of an FDA-approved drug.

What use did FDA evaluate TB-500 for?

FDA's TB-500 evaluation states that TB-500-related substances were evaluated for the use "wound healing." The BPC-157 proposed uses are not summarized here.

Where does FDA's Category 2 page list them?

Both appear under "Bulk drug substances nominated but withdrawn," as read on 17 November 2026.

What did HHS announce on 30 October 2026?

A draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances (91 FR 68526). Appendix A lists six peptides, including BPC-157 and TB-500.

Is the HHS policy binding?

The notice says the draft policy does not establish any rights for any person and is not binding on HHS or the public, and that HHS may revisit it.

What does the HHS policy document say about the advisory committee?

Appendix B states that the PCAC "voted in favor of inclusion" for BPC-157 and "in favor of both forms" for TB-500. No separate FDA vote record was found.

How do the WADA 2026 List entries differ?

BPC-157 is named under S0, Non-approved substances. TB-500 is named under S2.3 as a thymosin-ß4 derivative. Both sections are prohibited at all times.

What is TB-500 in these documents?

FDA describes a seven-amino-acid peptide with an acetyl group at the N-terminal leucine; Ho et al. (2012) describe N-acetylated LKKTETQ, the 17-23 segment of thymosin β4. The documents do not address full-length thymosin β4.

Does this article say whether anything is legal?

No. It reports what documents state, with dates, and draws no legal conclusion.

Related reading: Research Peptide Documents in 2026: HHS, FDA and WADA Read, Tirzepatide: FDA, HHS and WADA Documents Read, BPC-157 Regulatory Documents in 2026: A Dated Reading, PT-141 US Regulatory Status: A Primary-Source Summary.

References

  1. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register. 2026 Oct 30;91:68526-68527. Document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances (read 17 November 2026).
  2. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document with Appendices A and B). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf (read 17 November 2026).
  3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act; and Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov (both read 17 November 2026). 21 CFR 216.23, ecfr.gov (read 17 November 2026).
  4. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (event page) and FDA Briefing Documents, fda.gov/media/193342/download, /193343/download and /193349/download (read 17 November 2026).
  5. World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard. In force 1 January 2026. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (text read 17 November 2026).
  6. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043
  7. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H by LC-MS/MS. Drug Test Anal. 2017;9(10):1490-1498. doi:10.1002/dta.2152
  8. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.